HARMONIZE open-label extension of sotatercept in combined postcapillary and precapillary pulmonary hypertension with HFpEF

Phase 2, open-label, single-arm trial of sotatercept in pulmonary hypertension (PH), heart failure with preserved ejection fraction (HFpEF) and combined post-capillary and pre-capillary pulmonary hypertension, sponsored by Merck & Co. Primary endpoints: Number of participants who experience an adverse event and Number of participants who discontinue study treatment due to an adverse event. Planned start May 2025; status: authorised.